A CRA expert was retained in an antitrust matter involving patent settlement agreements between branded and generic pharmaceutical manufacturers that involved so-called ‘reverse payments’. Plaintiffs alleged that the agreements involved a conspiracy to fix prices and allocate markets, and that this conspiracy involved an exclusionary scheme to maintain a monopoly. CRA’s expert determined that generic versions of the drug would not likely have entered earlier absent the settlement agreements, the relevant market included competing branded products, and the agreements were not anticompetitive.
Examining physician practice groups’ options to manage rising administrative and operational complexities
Charles River Associates (CRA) was commissioned by McKesson to analyze the economic role of McKesson’s Management Services Organizations (MSOs) within the...